Inhibition of cytokine production and cytotoxic activity of human antimelanoma specific CD8+ and CD4+ T lymphocytes by adenosine-protein kinase A type I signaling

Cancer Research

Volumn 67, Issue 12, 2007, Pages 5949-5956

  Raskovalova, Tatiana ^a,b   Lokshin, Anna ^a,b   Huang, Xiaojun ^a,b   Su, Yunyun ^a,b   Mandic, Maja ^b   Zarour, Hassane M ^a,b   Jackson, Edwin K ^a   Gorelik, Elieser ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 2 CHLOROADENOSINE; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; ADENOSINE; ADENOSINE A2A RECEPTOR AGONIST; ADENOSINE A2A RECEPTOR ANTAGONIST; CD150 ANTIGEN; CHEMOKINE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYTOKINE; OKT 4; OKT 8; PROTEIN KINASE INHIBITOR;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; CYTOTOXICITY; ENZYME ACTIVATION; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE;

2-CHLOROADENOSINE; ADENOSINE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; MELANOMA; RECEPTOR, ADENOSINE A2A; SIGNAL TRANSDUCTION;

EID: 34250884676     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4249     Document Type: Article

References (43)

1. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006;24:175-208.
2. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001;411:380-4.
3. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
4. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 2006;66:5527-36.
5. Cronstein BN. Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 1994;76:5-13.
6. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in down-regulation of inflammation and protection from tissue damage. Nature 2001;414:916-20.
7. Sitkovsky MV, Lukashev D, Apasov S, et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 2004;22:657-82.
8. Sitkovsky MV, Ohta A. The "danger" sensors that STOP the immune response: the A2 adenosine receptors? Trends Immunol 2005;26:299-304.
9. Burnstock G. The past, present and future of purine nucleotides as signalling molecules. Neuropharmacology 1997;36:1127-39.
10. Blackburn MR, Aldrich M, Volmer JB, et al. The use of enzyme therapy to regulate the metabolic and phenotypic consequences of adenosine deaminase deficiency in mice. Differential impact on pulmonary and immunologic abnormalities. J Biol Chem 2000;275:32114-21.
11. Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 1972;2:1067-9.
12. Klinger M, Freissmuth M, Nanoff C. Adenosine receptors: G protein-mediated signalling and the role of accessory proteins. Cell Signal 2002;14:99-108.
13. Sitkovsky M, Lukashev D. Regulation of immune cells by local-tissue oxygen tension: HIF1α and adenosine receptors. Nat Rev Immunol 2005;5:712-21.
14. Hasko G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol 2004;25:33-9.
15. Ohta A, Gorelik E, Prasad SJ, et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A 2006;103:13132-7.
16. Blay J, White TD, Hoskin DW. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res 1997;57:2602-5.
17. Raskovalova T, Huang X, Sitkovsky M, Zacharia LC, Jackson EK, Gorelik E. Gs protein-coupled adenosine receptor signaling and lytic function of activated NK cells. J Immunol 2005;175:4383-91.
18. Huang S, Apasov S, Koshiba M, Sitkovsky M. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood 1997;90:1600-10.
19. Koshiba M, Kojima H, Huang S, Apasov S, Sitkovsky MV. Memory of extracellular adenosine A2A purinergic receptor-mediated signaling in murine T cells. J Biol Chem 1997;272:25881-9.
20. Erdmann AA, Gao ZG, Jung U, et al. Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. Blood 2005;105:4707-14.
21. Raskovalova T, Lokshin A, Huang X, Jackson EK, Gorelik E. Adenosine-mediated inhibition of cytotoxic activity and cytokine production by IL-2/NKp46-activated NK cells: involvement of protein kinase a isozyme I (PKAI). Immunologic Res 2006;36:91-9.
22. Lokshin A, Raskovalova T, Huang X, Zacharia LC, Jackson EK, Gorelik E. Adenosine-mediated inhibition of the cytotoxic activity and cytokine production by activated natural killer cells. Cancer Res 2006;66:7758-65.
23. Herin M, Lemoine C, Weynants P, et al. Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int J Cancer 1987;39:390-6.
24. + T cells. Cancer Res 2003;63:6506-15.
25. Gorelik E, Landsittel DP, Marrangoni AM, et al. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005;14:981-7.
26. Chin KV, Yang WL, Ravatn R, et al. Reinventing the wheel of cyclic AMP: novel mechanisms of cAMP signaling. Ann N Y Acad Sci 2002;968:49-64.
27. Skalhegg BS, Tasken K. Specificity in the cAMP/PKA signaling pathway. Differential expression regulation, and subcellular localization of subunits of PKA. Front Biosci 2000;5:D678-93.
28. Beebe SJ, Blackmore PF, Chrisman TD, Corbin JD. Use of synergistic pairs of site-selective cAMP analogs in intact cells. Methods Enzymol 1988;159:118-39.
29. Kawasaki H, Springett GM, Mochizuki N, et al. A family of cAMP-binding proteins that directly activate Rap1. Science 1998;282:2275-9.
30. de Rooij J, Zwartkruis FJ, Verheijen MH, et al. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 1998;396:474-7.
31. Enserink JM, Christensen AE, de Rooij J, et al. A novel Epac-specific cAMP analogue demonstrates independent regulation of Rap1 and ERK. Nat Cell Biol 2002;4:901-6.
32. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000;351:95-105.
33. Gjertsen BT, Mellgren G, Otten A, et al. Novel (Rp)-cAMPS analogs as tools for inhibition of cAMP-kinase in cell culture. Basal cAMP-kinase activity modulates interleukin-1β action. J Biol Chem 1995;270:20599-607.
34. Aandahl EM, Moretto WJ, Haslett PA, et al. Inhibition of antigen-specific T cell proliferation and cytokine production by protein kinase A type I. J Immunol 2002;169:802-8.
35. Laxminarayana D, Berrada A, Kammer GM. Early events of human T lymphocyte activation are associated with type I protein kinase A activity. J Clin Invest 1993;92:2207-14.
36. Torgersen KM, Vang T, Abrahamsen H, Yaqub S, Tasken K. Molecular mechanisms for protein kinase A-mediated modulation of immune function. Cell Signal 2002;14:1-9.
37. Bryce PJ, Dascombe MJ, Hutchinson IV. Immunomodulatory effects of pharmacological elevation of cyclic AMP in T lymphocytes proceed via a protein kinase A independent mechanism. Immunopharmacology 1999;41:139-46.
38. Staples KJ, Bergmann M, Tomita K, et al. Adenosine 3′,5′- cyclic monophosphate (cAMP)-dependent inhibition of IL-5 from human T lymphocytes is not mediated by the cAMP-dependent protein kinase A. J Immunol 2001;167:2074-80.
39. Sugiyama H, Chen P, Hunter M, Taffs R, Sitkovsky M. The dual role of the cAMP-dependent protein kinase Cα subunit in T-cell receptor-triggered T-lymphocytes effector functions. J Biol Chem 1992;267:25256-63.
40. Sugiyama H, Chen P, Hunter MG, Sitkovsky MV. Perturbation of the expression of the catalytic subunit Ca of cyclic AMP-dependent protein kinase inhibits TCR-triggered secretion of IL-2 by T helper hybridoma cells. J Immunol 1997;158:171-9.
41. Cho-Chung YS, Nesterova M, Becker KG, et al. Dissecting the circuitry of protein kinase A and cAMP signaling in cancer genesis: antisense, microarray, gene overexpression, and transcription factor decoy. Ann N Y Acad Sci 2002;968:22-36.
42. Kirschner LS, Kusewitt DF, Matyakhina L, et al. A mouse model for the Carney complex tumor syndrome develops neoplasia in cyclic AMP-responsive tissues. Cancer Res 2005;65:4506-14.
43. Gattinoni L, Powell DJ, Jr., Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006;6:383-93.